| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Research Division, Ochsner Clinic Foundation, New Orleans, Louisiana 70121
PEPTIDE HORMONES and
growth factors are known to act by binding to cell surface receptors
and subsequently activating intracellular mediators of signal
transduction. Over the last three decades evidence has accumulated to
indicate that at least some peptide hormones and growth factors also
bind and act in the cellular interior either after internalization by
target cells or retention in their cells of synthesis
(1-67). Several years ago our laboratory (48,
53) proposed the term intracrine for such intracellularly acting
peptides hormones irrespective of whether their binding/action followed
internalization or occurred in the cell that synthesized them. In fact,
many intracrines act in both fashions. Intracrines not infrequently are
synthesized as isoforms, and in some cases, one isoform binds to an
intracellular site in its cell of synthesis while another is secreted
(47, 51, 52). In some cases, intracellular intracrine
binding can be associated with clear biological effect. For example,
the angiogenic protein angiogenin stimulates endothelial cell
proliferation, either directly or indirectly, only after translocation
to the nucleus of target endothelial cells (34, 47, 51,
52). A similar dependence on nuclear translocation for the
stimulation of proliferation is displayed by fibroblast growth factor-2
(FGF-2) (3). In some cases, the intracellular action of an
intracrine factor is similar to the action the factor exerts after cell
membrane binding, but in some cases it is not. For example, parathyroid
hormone-related protein inhibits mitogenesis of vascular smooth muscle
cells following cell surface binding but stimulates mitosis following
nuclear binding (1, 2, 47, 51, 52). Although in many cases
biological action has been shown in association with intracellular
intracrine binding, insufficient work has been done to date on the
possible intracellular actions of peptide growth factors/hormones to
make demonstrated intracellular biological function a requirement for
ascribing intracrine status to a protein. Rather, the binding of a
signaling protein to an intracellular organelle not associated with the secretory or degratory pathways, or the demonstration of an
intracellular action of bound hormone, will be taken here as evidence
of intracrine status. Although intracrine binding need not be
restricted to any one intracellular organelle (for example, angiotensin
II binds to both nuclei and mitochondria), the great majority of
intracrines reported to date traffic to nucleus and often to nuclelous.
Implicit in the definition of intracrine employed here is the fact that
intracrine status is defined functionally (i.e., by intracellular
binding/action of a peptide factor that is active outside the cell)
rather than structurally (except insofar as all intracrines are here
required to be peptides). As it happens, a great structural diversity
is to be found among intracrines. Cytokines such as interleuken-6, G
protein-coupled receptor activating hormones such as angiotensin,
growth factors such as insulin, as well as homeoproteins such as
Engrailed 1 and 2 and Hoxa 5, and enzymes such as platelet-derived
endothelial cell growth factor (PDECGF-thymidine phosphorylase) all are
putative intracrines (Table 1) (6,
32, 43, 47, 51, 52, 65, 67). With the exception of
renin-prorenin, all the factors listed in Table 1 have been reported in
the nucleus. Against this background, we have recently made proposals
regarding the origin and actions of intracrines. These notions
suggested 1) that higher order functionalities could result
from the establishment of intracellular intracrine regulatory feedback
loops, and 2) that some intracellular regulatory proteins
may in fact be intracrines with extracellular functions (47,
50-52). Here the actions of several intracrines will be reviewed to begin to explore the potential relevance of intracrine functionality for physiology and medicine.
ARTICLE
TOP
ARTICLE
REFERENCES
Table 1.
Representative intracrines
Intracrine Renin Angiotensin System
The renin angiotensin system (RAS) is one of the more intensively studied physiological systems in higher organisms. Appreciated as an important regulator of cardiovascular homeostasis, recent evidence has indicated that local RAS, complete or partial, exist and operate in a variety of tissues under various circumstances (49). One is then lead to ask whether the RAS could also operate in the intracellular arena; i.e., in an intracrine mode (iRAS). More than three decades ago it was reported (47, 48, 50-53) that labeled angiotensin trafficked from the circulation and localized to cardiac myocyte nuclei and to mitochondria. Ten years later, our group (47) reported specific angiotensin receptors in isolated nuclei and associated with chromatin; angiotensin binding to those receptors increased gene transcription. Nuclear angiotensin receptors were subsequently reported to be At-1-like in that they were blocked by losartan, and these reports showed receptors were present in association with both the nuclear membrane and, again, with chromatin. Confirmation that binding of angiotensin to isolated nuclei resulted in increased gene transcription was later provided by the observation that nuclear angiotensin upregulates renin, angiotensinogen, and platelet-derived growth factor (PDGF) transcription (9, 10, 12, 47, 48, 50-53). Moreover, electron microscopic immunohistochemical techniques were used to demonstrate angiotensin II immunoreactivity located in association with the euchromatin of cerebellar neurons, hepatocytes, and adrenal cells from normal animals (13). Also confocal microscopy studies demonstrated that functional fluorescent-labeled At-1 receptors traffic to the nuclear interior upon agonist binding (7). In addition, the direct introduction of angiotensin or renin into the intracellular space produced alterations in calcium flux and conductance in cardiac myocytes (11, 14, 47). Thus considerable evidence has been developed in several laboratories to indicate the existence of functional intracellular angiotensin receptors.Adrenal Intracrine RAS
A local tissue RAS is known to be present in the adrenal, and the likely existence of an adrenal intracellular RAS has recently been reported (8, 40). The activity of this intracellular renin system is unmasked by nephrectomy, which all but eliminates plasma renin activity, but upregulates adrenal renin with the result that aldosterone secretion is increased by local renin and hyperkalemia. Both full-length renin destined for secretion and so-called renin exon 1A, encoded by a transcript lacking the sequences for the secretory signal piece and therefore expected to remain intracellular, are found in adrenal cells (8, 28, 40, 60). Transcripts identical or similar to renin exon 1A have been reported by several investigators, initially in the brain and subsequently in other tissues (8, 28, 60). Of note, renin exon 1A appears to be synthesized as an active renin, as opposed to prorenin. Also, adrenal mitochondrial renin granules increase following nephrectomy (40). Because renin exon 1A traffics to mitochondria (which have angiotensin receptors), it is likely that renin exon 1A is upregulated by nephrectomy, traffics to mitochondria, generates angiotensin, and stimulates aldosterone secretion. Thus in rats maintained long term by dialysis after nephrectomy, renin synthesis by adrenal cells increases and aldosterone production is maintained (40). This aldosterone secretion is inhibited by the angiotensin receptor blocker losartan. However, when angiotensin is infused into these animals, aldosterone synthesis actually falls, likely because of the suppression of local renin. These results suggest that intracellular angiotensin may be more potent in the stimulation of aldosterone secretion than extracellular angiotensin and also suggest that losartan can be internalized to inhibit intracellular angiotensin action (40).Renin-Prorenin Internalization
Receptors for prorenin and renin exist on a variety of cell types (36, 37, 39, 54, 58). Prorenin internalization via the mannose/insulin-like growth factor-II (IGF-II) receptor with subsequent intracellular activation has been reported (54). A high-affinity renin receptor has also been reported that binds prorenin, is coupled to an intracellular signaling system, and produces a biological effect (36, 37). The presence of this receptor in the mesangium, as well as the vascular smooth muscles cells of coronary arteries, suggests the possibility that renin exerts a direct biological effect in the vasculature. Binding of renin to this receptor is also associated with an enhanced ability of the enzyme to generate angiotensin I in the extracellular space, thereby providing a second mechanism by which ligand binding to the receptor produces a biological action (36, 37). Also, recent studies in transgenic animals have indicated that prorenin can be internalized by cardiac and vascular cells by a mechanism different from the mannose-IGF-II receptor pathway and can then generate angiotensin II after internalization and activation (39). This internalized, activated prorenin causes both hypertension and cardiac injury. These results suggest that the mannose-IGF-II pathway may be degradative, whereas the second internalization pathway results in functional intracellular renin. In any case, the multiple reports of renin activity in the heart (for the most part under pathological conditions or in normal development), the upregulation of renin exon 1A in the ventricles following myocardial infarction, and the ability of prorenin to be internalized/activated by cardiac cells all point to the existence of functional intracellular renin (8, 39, 49).Intracellular Angiotensin
Our group recently studied rat hepatoma cells expressing renin and angiotensin-converting enzyme. Transfection of these cells with an angiotensinogen construct lacking the signal sequence encoding region, and therefore likely to produce a nonsecreted angiotensinogen, led to enhanced proliferation, which was blocked by the At-1 blocker losartan and phenylarsine oxide (an inhibitor of receptor internalization) but not by the insurmountable At-1 blocker candesartan CV-11974 (the active candesartan moiety) or anti-angiotensin II antibodies (9, 10). PDGF gene transcription was upregulated in the transfected cells, and their enhanced proliferation was partially blocked by anti-PDGF antibodies. The most likely explanation for these findings is that the angiotensinogen construct was cleaved to release angiotensin II in the intracellular space and thereafter upregulated a series of genes (including PDGF), which stimulated proliferation. Losartan blocked the action of intracellular angiotensin after receptor-dependent internalization. In particular, we have shown that the large isoform of PDGF was upregulated in the transformed cells, and this effect was blocked by losartan but not candesartan CV-11974. Although it frequently has been assumed that nonpeptide angiotensin II antagonists are not internalized after receptor binding, this has not actually been shown for losartan (9, 10, 33, 52). Indeed, a recent study employing confocal microscopy demonstrated clear internalization of angiotensin II receptors following the administration of losartan (33). It is also noteworthy that these hepatoma cells expressed so-called exon-1A renin-a transcript predicted to produce an active renin (as opposed to prorenin) and to remain intracellular because it lacks a secretory signal sequence (8, 49).Collectively, these findings suggest the existence of intracrine angiotensin action and also again raise the possibility that a complete iRAS exists in some cells (53). An additional point can be made. Renin and prorenin are secreted and circulate in the blood. Cellular receptors have been reported for prorenin and renin, and binding of renin and prorenin to some of these receptors produces a biological action either as a result of the generation of angiotensin in the extracellular space, prorenin internalization, and activation, or as a direct result of receptor binding (36, 37, 39, 49, 54, 58). Moreover, as noted above, intracellular angiotensin and renin are biologically active. Thus not only angiotensin II, but renin and prorenin, can be considered intracrines. The existence of renin exon-1A indicates that renin, like other intracrines, is synthesized in more than one form with one or more isoforms acting intracellularly. It is noteworthy that des-angiotensin-I-angiotensinogen is a member of the serpin family of proteins (like the intracrines pigment epithelium-derived factor and maspin) and is anti-angiogenic, but as yet, no intracellular binding/action of this protein has been described (5).
Clinical implications. The existence of intracrine renin-angiotensin action could be clinically important. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) that enter cells could have different pharmacological activities than those that do not. Whereas no such differences have as yet been reported, it would be worthwhile to look for them, although they would be expected to be more likely related to long-term effects on growth and differentiation than to blood pressure or hemodynamic alterations. Because renin exon-1A has been reported to be the only renin upregulated in the ventricles of rats following myocardial infarction, ACEIs and ARBs that act in cells may exert therapeutic effects different from those that act only outside the cell in patients who have suffered myocardial infarction. The observation that prorenin can be taken up into cardiac cells, activated, and produce pathology raises the possibility that ACEIs and ARBs that act in the intracellular space could prevent other forms of cardiovascular disease, possibly including some forms of arrhythmia given the effects of intracellular angiotensin on intercellular conductance. From the role played by angiotensin in the genesis of left ventricular hypertrophy, cardiac fibrosis, and cardiac aldosterone synthesis, it appears reasonable to consider the possible participation of the iRAS in these processes as well (49). The contention that renin is not simply a circulating aspartyl protease but is a hormone and an intracrine in its own right may be startling. Nonetheless, the available evidence indicates that renin and angiotensin are active within cells. A fuller understanding of the iRAS could open new avenues of research and therapy and lead to a search for intracrine analogs of other established physiological systems.
Angiogenesis
Many intracrines are angiogenic (e.g., angiogenin, FGF-2, and angiotensin) or anti-angiogenic (e.g., pigment epithelium-derived factor maspin) either directly or through the stimulation of an angiogenic factor such as vascular endothelial growth factor (VEGF), which itself has recently been shown to be an intracrine (29, 47, 51, 52). As already noted, angiogenin, an RNase, must be internalized by target endothelial cells and traffic to nucleolus to stimulate, either directly or indirectly, the cellular proliferation essential for angiogenesis (34, 47, 51, 52). A similar requirement for nuclear translocation in stimulating proliferation is seen in the case of some other intracrines such as FGF-2 (3, 47). Most identified intracrines have been shown to traffic to nucleus (renin and prorenin are exceptions so far) as well as in some cases to other intracellular organelles (47, 51, 52). It has been suggested that nuclear translocation of angiogenic factors was an essential feature of their action (34). Indeed, it is the case that virtually every intracrine that traffics to nucleolus is either directly or indirectly angiogenic or anti-angiogenic. Nuclear but not nucleolar binding has been reported in the case of other angiogenic intracrines (e.g., angiotensin and VEGF) (29, 47, 51, 52). Another link between intracrine action and the nucleolus is the fact that the pleurifunctional nucleolar protein nucleolin, which regulates rDNA transcription and participates in ribosomal synthesis, also is a cell surface protein, which shuttles the angiogenic intracrines pleiotrophin and midkine from the cell surface to nucleus (47, 51, 52). Given the likelihood that the nucleolus is an ancient functional unit of the eukaryotic cell and given the binding of many intracrines to the nucleolus, it can be hypothesized that intracrines first acted at the nucleolus and thereafter assumed additional roles in the cell and in extracellular signaling (38, 47, 51, 52). An additional implication of the frequent association of nucleolar binding and angiogenesis is the possibility that the endothelial cell continues to use ancient regulatory mechanisms and in that sense may be more primitive or pleurifunctional than other cells (52).Clinical implications. Angiogenesis and vasculogenesis play important roles not only in the development but also in a variety of pathological conditions such as ischemic revascularization and tumor angiogenesis. These processes are complex and are under the influence of competing angiogenic/anti-angiogenic inputs. For example, angiotensin is angiogenic, and this effect appears to be mediated by the At-1 receptor; angiotensin binding to the At-2 receptor produces apoptosis and can be anti-angiogenic (59). Many intracrines are pro-apoptotic or anti-angiogenic, and it appears likely that understanding the nature of the interaction of pro- and anti-angiogenic intracrine factors will be important to the design of effective revascularization and anti-tumor strategies, be they gene therapy based like VEGF gene therapy or based on more traditional pharmaceuticals (50). For example, it has been shown (34, 47, 51, 52) that the angiogenic effect of angiogenin is dependent on not only the nucleolar trafficking and RNase activity of the protein, but also on its ability to stimulate rRNA synthesis. Drugs designed to inhibit this action of the protein could be expected to inhibit tumor angiogenesis produced by angiogenin and perhaps by other intracrines as well (34, 66).
Homeoproteins
Homeodomain transcription factors, or homeoproteins, are regulators of gene expression and play an important role in a variety of processes, most notably development. They are large complex molecules possessing DNA binding capacity and interact with other transcription factors and homeproteins to coordinate embryonic tissue patterning and development. Homeoproteins contain a 60-amino acid DNA-binding domain known as the homeodomain composed of three
-helices, the third of which is important for cognate DNA binding. In the context of this essay they are of particular interest because there is a body of evidence to suggest these proteins may function in
an intracrine mode (6, 26, 31, 42, 44, 52). In the early
1990s it was discovered that the homeodomain of the Drosophila transcription factor Antennapedia is internalized
by cultured cells. The internalization does not depend on traditional endocytosis and involves translocation of the protein into the cytoplasm and then to the nucleus. It was subsequently reported that
the homeodomains of Fushi tarazu, Hoxa 5, Hoxa 8, and Engrailed are
internalized. Moreover, the entire mammalian homeoproteins Engrailed
and Hoxa 5 are internalized, and the latter has been shown to traffic
to the nucleus. The third helix of the homeodomain was shown to be
important for internalization. Subsequent studies demonstrated that
transfected COS-7 cells can secrete Engrailed 2 with subsequent uptake
of the protein by embryonic neurons in coculture. The secretion of
Engrailed does not involve a traditional secretory signal but rather is
dependent on a sequence located between the second and third helices of
the homeodomain (6, 26, 31, 42, 44). Collectively, these
studies indicate that at least some homeotranscription factors are
intracrines. This conclusion is consistent with the concept of the
intracrine, which as described above, is based on functionality rather
than structure. Indeed, the variety of intracrine structures suggests an ancient origin for intracrine functionality. To be sure, a recent
report (31) raises the possibility that the apparent internalization of positively charged DNA binding proteins may be the
result of fixation artifacts. Studies of homeoprotein internalization in living (nonfixed) cells therefore must be performed. However, there
exists considerable functional data supporting the internalization of
these proteins (as exemplified by the penetratins; see below) (6,
26, 44). In any case, the view of intracrine functionality developed here is not dependent on the intracrine action of homeodomain and other DNA binding proteins, but rather is consistent with it.
Moreover, the notion that intracrines and transcription factors are
related derives support from observations related to plant transcription factors and viral proteins such as Tat (24, 30, 47,
51, 52, 67). This laboratory has previously suggested that this
phenomenon derives from the origins of intracrines as regulators of
cellular memory and differentiation on the one hand and of metazoan
development on the other (47, 51, 52).
Clinical implications. The implications of homeoprotein intracrine action could be wide ranging. First, slightly modified versions of the third helix of the Antennapedia homeodomain have been employed as carriers for the intracellular transfer of proteins. Known as penetratins, these peptides can be designed to deliver fusion proteins into the cytoplasm only or into the cytoplasm and nucleus (26, 44). They are being used as vehicles for protein transfer in research studies and have the potential to serve as the basis for a new class of pharmaceuticals. Interestingly, other nuclear proteins apparently can be taken up by target cells, and at least one of these is an intracrine (25, 41, 55, 63). This phenomenon of nuclear protein uptake by cells suggests the possibility of an extracellular signaling role for nuclear regulatory proteins early in metazoan development and raises the possibility that from these origins evolved the intracrines of today.
Intracrines are involved in the differentiation of a variety of cells, and this coupled with the observation that homeoproteins can be intracrines suggests the possibility that some intracellular regulatory proteins, and in particular homeoproteins, could be made to function therapeutically as intracrines. One candidate for such application is the islet-cell-inducing homeoprotein PDX1 (52, 62). Much will depend on determining exactly how these DNA binding proteins are taken up from the extracellular space. Similarly, the wide-range differentiating actions of other intracrines could well be useful in recruiting and maintaining various stem cell populations for therapeutic use (1, 25, 42, 47, 51, 52).Future Directions
The view of intracrine action outlined here generates testable predictions based on the proposed intracrine feedback loops and novel functions of intracellular regulatory proteins. These are discussed elsewhere and could have implications for clinical care (47, 50-52). For example, the argument made here suggests the possibility that the tumor suppressor protein p53 could be an intracrine; it traffics to nucleolus, is anti-angiogenic, exists in multiple isoforms, and is a regulator of transcription. If correct, this would imply that p53 (or a p53 fragment or homologue) could be active outside cells (51, 52). The fact that many intracrines regulate cellular development suggests the possibility that these factors will increasingly find applications in the recruitment of stem cells of various sorts for therapeutic purposes. Also, the accumulating evidence for intracellular interactions between intracrines, as well as between intracrines and transcription factors, suggests that the study of these interactions and the regulatory loops they appear to form could yield valuable insights into cellular physiology. For example, the intracrine dynorphin B after nuclear binding upregulates transcription of its precursor preprodynorphin. Nuclear angiotensin binding upregulates renin and angiotensinogen transcription. PDX1 upregulates its own transcription as well as transcription of insulin, itself an intracrine. The intracrine dynorphin B can indirectly upregulate transcription of the intracrine FGF-3 (16, 35, 47, 51, 52). Other examples could be given, and many others undoubtedly remain to be discovered. These interactions, and the feedback loops they potentially produce, provide the substrate for the development of considerable regulatory complexity within the cell and arguably form the basis of a physiology of intracrines with implications for angiogenesis, growth, hormonal responsiveness, and development. It must also be recalled that intracrines bind and act at organelles other than the nucleus such as mitochondria, endocytotic vesicles, and golgi. The exploration of these activities will also be important.Irrespective of the validity of the expanded view of intracrine action proposed here, intracrine peptide hormone action is a reality. The implications of intracrine action are only now being investigated, but every indication is that intracrine action is physiologically relevant. Indeed, the intracrine concept could influence the direction of physiology research in important ways by 1) stimulating the exploration for the intracellular analogs of well-established homeostatic systems such as the RAS, and 2) suggesting an expanded view of the mechanisms of differentiation and homeostasis in cells and tissues, i.e.,, by suggesting an expanded view of cellular physiology.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: R. N. Re, Research Division, Ochsner Clinic Foundation, New Orleans, LA 70121 (E-mail: rre{at}ochsner.org).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpheart.00935.2002
| |
REFERENCES |
|---|
|
TOP
ARTICLE
REFERENCES
|
|---|
1.
Aarts, MM,
Davidson D,
Corlukja A,
Petroulakis E,
Guo J,
Bringhurst FR,
Galipeau J,
and
Henderson JE.
PTHrP promotes quiescence and survival of serum deprived chondrocytes by inhibiting rRNA synthesis.
J Biol Chem
276:
37934-37943,
2001
2.
Aarts, MM,
Levy D,
He B,
Stregger S,
Chen T,
Richard S,
and
Henderson JE.
Parathyroid hormone-related protein interacts with RNA.
J Biol Chem
27:
4832-4838,
1999.
3.
Bouche, G,
Gas N,
Prats H,
Baldin V,
Tauber JP,
Teissie J,
and
Amalric F.
Basic fibroblast growth factor enters the nucleolus and stimulates the transcription of ribosomal genes in ABAE cells undergoing G0-G1 Transition.
Proc Natl Acad Sci USA
84:
6770-6774,
1987
4.
Butler, LM,
Zhou X,
Xu WS,
Scher HI,
Rifkind RA,
Marks PA,
and
Richon VM.
The histone deacetylase inhibitor SAHA arrests cancer cell growth, upregulates thioredoxin-binding protein-2, and downregulates thioredoxin.
Proc Natl Acad Sci USA
99:
11700-11705,
2002
5.
Celerier, J,
Cruz A,
Lamande N,
Gasc JM,
and
Corvol P.
Angiotensinogen and its cleaved derivatives inhibit angiogenesis.
Hypertension
39:
224-228,
2002
6.
Chatelin, L,
Volovitch M,
Joliot AH,
Perez F,
and
Prochiantz A.
Transcription factor hoxa-5 is taken up by cells in culture and conveyed to their nuclei.
Mech Dev
55:
111-117,
1996[Web of Science][Medline].
7.
Chen, R,
Mukhin YV,
Garnovskaya MN,
Thielen TE,
Iijima Y,
Huang C,
Raymond JR,
Ullian ME,
and
Paul RV.
A functional angiotensin II receptor-GFP fusion protein: evidence for agonist-dependent nuclear translocation.
Am J Physiol Renal Physiol
279:
F440-F448,
2000
8.
Clausmeyer, S,
Reinecke A,
Farrenkopf R,
Unger T,
and
Peters J.
Tissue-specific expression of a rat renin transcript lacking the coding sequence for the prefragment and its stimulation by myocardial infarction.
Endocrinology
141:
2963-2970,
2000
9.
Cook, JL,
Giardina JF,
Zhang Z,
and
Re RN.
Intracellular angiotensin II increases the long isoform of PDGF mRNA in rat hepatoma cells.
J Cell Mol Cardiol
34:
1525-1537,
2002.
10.
Cook, JL,
Zhang Z,
and
Re RN.
In vitro evidence for an intracellular site of angiotensin action.
Circ Res
89:
1138-1146,
2001
11.
De Mello, WC,
and
Danser AHJ
Angiotensin II and the heart: on the intracrine rennin angiotensin system.
Hypertension
35:
1183-1188,
2000
12.
Eggena, P,
Zhu JH,
Sereevinyayut S,
Giordani M,
Clegg K,
Andersen PC,
Hyun P,
and
Barrett JD.
Hepatic angiotensin II nuclear receptors and transcription of growth-related factors.
J Hypertens
14:
961-968,
1996[Web of Science][Medline].
13.
Erdmann, B,
Fuxe K,
and
Ganten D.
Subcellular localization of angiotensin II immunoreactivity in the rat cerebellar cortex.
Hypertension
28:
818-824,
1996
14.
Eto, K,
Ohya Y,
Nakamura Y,
Abe I,
and
Iida M.
Intracellular angiotensin II stimulates voltage-operated Ca channels in arterial myocytes.
Hypertension
39:
474-478,
2002
15.
Fox, SB,
Moghaddam A,
Westwood M,
Turley H,
Bicknell R,
Gatter KC,
and
Harris AL.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.
J Pathol
176:
183-190,
1995[Web of Science][Medline].
16.
Gemel, J,
Jacobsen C,
and
MacArthur CA.
Fibroblast growth factor-8 expression is regulated by intronic engrailed and Pbx1-binding sites.
J Biol Chem
274:
6020-6026,
1999
17.
Gortz, A,
Nibbs RJ,
McLean P,
Jarmin D,
Lambie W,
Baird JW,
and
Graham GJ.
The chemokine ESkine/CCL27 displays novel modes of intracrine and paracrine function.
J Immunol
169:
1387-1394,
2002
18.
Grasl-Kraupp, B,
Schausberger E,
Hufnagl K,
Gerner C,
Low-Baselli A,
Rossmanith W,
Parzefall W,
and
Schulte-Hermann R.
A novel mechanism for mitogenic signaling via pro-transforming growth factor alpha within hepatocyte nuclei.
Hepatology
35:
1372-1380,
2002[Web of Science][Medline].
19.
Harris, RC.
Potential mechanisms and physiologic actions of intracellular angiotensin II.
Am J Med Sci
318:
374-379,
1999[Web of Science][Medline].
20.
Henderson, JE.
Nuclear targeting of secretory proteins.
Mol Cell Endocrinol
129:
1-5,
1997[Web of Science][Medline].
21.
Jans, DA,
Briggs LJ,
Jans P,
Groelich CJ,
Parasivam G,
Kumar S,
Sutton VR,
and
Trapani JA.
Nuclear targeting of the serine protease granzyme A (fragmentin-1).
J Cell Sci
111:
2645-2654,
1998[Abstract].
22.
Jans, DA,
and
Hassan G.
Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling?
Bioessays
20:
400-411,
1998[Web of Science][Medline].
23.
Jans, DA,
Jans P,
Briggs LJ,
Sutton V,
and
Trapani JA.
Nuclear transport of granzyme B (fragmentin-2). Dependence of perforin in vivo and cytosolic factors in vitro.
J Biol Chem
271:
30781-30789,
1996
24.
Jenik, PD,
and
Irish VF.
The Arabidopsis floral homeotic gene APETALA3 differentially regulates intercellular signaling required for petal and stamen development.
Development
128:
13-23,
2001[Abstract].
25.
Jiang, Y,
Jahagirdar BN,
Reinhardt RL,
Schwartz RE,
Keene CD,
Ortiz-Gonzalez XR,
Reyes M,
Lenvik T,
Lund T,
Blackstad M,
Du J,
Aldrich S,
Lisberg A,
Low WC,
Largaespada DA,
and
Verfaillie CM.
Pleuripotency of mesenchymal stem cells derived from adult marrow.
Nature
418:
41-49,
2002[Medline].
26.
Joliot, A,
Maizel A,
Rosenberg D,
Trembleau A,
Dupas S,
Volovitch M,
and
Prochiantz A.
Identification of a signal sequence necessary for the unconventional secretion of engrailed homeoprotein.
Curr Biol
8:
856-863,
1998[Web of Science][Medline].
27.
Karimpour, S,
Lou J,
Lin LL,
Rene LM,
Lagunas L,
Ma X,
Karra S,
Bradbury CM,
Markovina S,
Goswami PC,
Spitz DR,
Hirota K,
Kalvakolanu DV,
Yodoi J,
and
Gius D.
Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation.
Oncogene
21:
6317-6327,
2002[Web of Science][Medline].
28.
Lee-Kirsch, MA,
Gaudet F,
Cardoso MC,
and
Lindpaintner K.
Distinct renin isoforms generated by tissue-specific transcription initiation and alternative splicing.
Circ Res
84:
240-246,
1999
29.
Li, W,
and
Keller G.
VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells.
J Cell Sci
113:
1525-1534,
2000[Abstract].
30.
Lucas, WJ,
Bouche-Pillon S,
Jackson DP,
Nguyen L,
Baker L,
Ding B,
and
Hake S.
Selective trafficking of KNOTTED 1 homeodomain protein and its mRNA through plasmodesmata.
Science
270:
1980-1983,
1995
31.
Lundberg, M,
and
Johansson M.
Positively charged DNA-binding proteins cause apparent cell membrane translocation.
Biochem Biophys Res Commun
291:
367-371,
2002[Web of Science][Medline].
32.
Matsukawa, K,
Moriyama A,
Kawai Y,
Asai K,
and
Kato T.
Tissue distribution of human gliostatin/platelet-derived endothelial cell growth factor (PD-ECGF) and its drug-induced expression.
Biochim Biophys Acta
1314:
71-82,
1996[Medline].
33.
Merjan, AJ,
Kanashiro CA,
Krieger JE,
Han SW,
and
Paiva ACM
Ligand-induced endocytosis and nuclear localization of angiotensin II receptors expressed in CHO cells.
Braz J Med Biol Res
34:
1175-1183,
2001[Web of Science][Medline].
34.
Moroianu, J,
and
Riordan JF.
Nuclear translocation of angiogenic proteins in endothelial cells: an essential step in angiogenesis.
Biochemistry
33:
12535-12539,
1994[Medline].
35.
Murakami, A,
Ishida S,
and
Dickson C.
GATA-4 interacts distinctively with negative and positive regulatory elements in the Fgf-3 promoter.
Nucleic Acids Res
30:
1056-1064,
2002
36.
Nguyen, G,
Delarue F,
Berrou J,
Rondeau E,
and
Sraer JD.
Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen.
Kidney Int
50:
1897-1903,
1996[Web of Science][Medline].
37.
Nguyen, G,
Delarue F,
Burckle C,
Bouzhir L,
Giller T,
and
Sraer JD.
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.
J Clin Invest
109:
1417-1427,
2002[Web of Science][Medline].
38.
Pederson, T.
The pluerifunctional nucleolus.
Nucleic Acids Res
26:
3871-876,
1998
39.
Peters, J,
Farrenkopf R,
Clausmeyer S,
Zimmer J,
Kantachuvesiri S,
Sharp MGF,
and
Mullins JJ.
Functional significance of prorenin internalization in the rat heart.
Circ Res
90:
1135-1141,
2002
40.
Peters, J,
Obermüller N,
Woyth A,
Peters B,
Maser-Gluth C,
Kranzlin B,
and
Gretz N.
Losartan and angiotensin II inhibit aldosterone production in anephric rats via different actions on the intraadrenal renin-angiotensin system.
Endocrinology
140:
675-682,
1999
41.
Porkka, K,
Laakkonen P,
Hoffman JA,
Bernasconi M,
and
Ruoslahti E.
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo.
Proc Natl Acad Sci USA
99:
7444-7449,
2002
42.
Prochiantz, A.
Homeodomaine-derived peptides. In and out of the cells.
Ann NY Acad Sci
886:
172-179,
1999[Web of Science][Medline].
43.
Prochiantz, A.
Proteines messageres (Messenger proteins, French).
J Soc Biol
194:
119-123,
2000[Medline].
44.
Prochiantz, A,
and
Theodore L.
Nuclear/growth factors.
Bioessays
17:
39-44,
1995[Web of Science][Medline].
45.
Rakowicz-Szulczynska, EM.
Chromatin receptors for growth fractors.
In: Nuclear Localization of Growth Factors and of Monoclonal Antibodies. Boca Raton, FL: CRC, 1994, p. 3-102.
46.
Rakowicz-Szulczynska, EM,
and
Koprowski H.
Antagonistic effect of PDGF and NGF on transcription of ribosomal DNA and tumor cell proliferation.
Biochem Biophys Res Commun
163:
649-656,
1989[Web of Science][Medline].
47.
Re, R.
The nature of intracrine peptide hormone action.
Hypertension
34:
534-538,
1999
48.
Re, RN.
The cellular biology of angiotensin: paracrine, autocrine and intracrine action in cardiovascular tissues.
J Mol Cell Cardiol
21, Suppl5:
63-69,
1989[Web of Science][Medline].
49.
Re, RN.
The clinical implication of tissue renin angiotensin systems.
Curr Opin Cardiol
16:
317-327,
2001[Web of Science][Medline].
50.
Re, RN.
On the biological actions of intracellular angiotensin (Editorial).
Hypertension
35:
1189-1190,
2000
51.
Re, RN.
The origins of intracrine hormone action.
Am J Med Sci
323:
43-48,
2002[Web of Science][Medline].
52.
Re, RN.
Toward a theory of intracrine hormone action.
Regul Pept
106:
1-6,
2002[Web of Science][Medline].
53.
Re, RN,
and
Bryan SE.
Functional intracellular renin-angiotensin systems may exist in multiple tissues.
Clin Exp Hypertens
A6, Suppl10-11:
1739-1742,
1984.
54.
Saris, JJ,
van den Eijnden MM,
Lamers JM,
Saxena PR,
Schalekamp MA,
and
Danser AHJ
Prorenin-induced myocyte proliferation. No role for intracellular angiotensin.
Hypertension
39:
573-577,
2002
55.
Scaffidi, P,
Misteli T,
and
Bianchi ME.
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.
Nature
418:
191-195,
2002[Medline].
56.
Schedlich, LJ,
Le Page SL,
Firth SM,
Briggs LJ,
Jans DA,
and
Baxter RC.
Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit.
J Biol Chem
275:
23462-23470,
2000
57.
Schedlich, LJ,
Young TF,
Firth SM,
and
Baxter RC.
Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells.
J Biol Chem
273:
18347-18352,
1998
58.
Sealey, JE,
Catanzaro DF,
Lavin TN,
Gahnem F,
Pitarresi T,
Hu LF,
and
Laragh JH.
Specific prorenin/renin binding (ProBP). Identification and characterization of a novel membrane site.
Am J Hypertens
9:
491-502,
1996[Web of Science][Medline].
59.
Silvestre, JS,
Tamarat R,
Senbonmatsu T,
Icchiki T,
Ebrahimian T,
Iglarz M,
Besnard S,
Duriez M,
Inagami T,
and
Levy BI.
Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb.
Circ Res
90:
1072-1079,
2002
60.
Sinn, PL,
and
Sigmund CD.
Identification of three human renin mRNA isoforms from alternative tissue-specific transcriptional initiation.
Physiol Genomics
3:
25-31,
2000
61.
Srivastava, M,
and
Pollard HB.
Molecular dissection of nucleolin's role in growth and cell proliferation: new insights.
FASEB J
13:
1911-1922,
1999
62.
Stoffers, DA,
Kieffer TJ,
Hussain MA,
Drucker DJ,
Bonner-Weir S,
Habener JF,
and
Egan JM.
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.
Diabetes
49:
741-748,
2000[Abstract].
63.
Taguchi, A,
Blood DC,
del Toro G,
Canet A,
Lee DC,
Qu W,
Tanji N,
Lu Y,
Lalla E,
Fu C,
Hofmann MA,
Kislinger T,
Ingram M,
Lu A,
Tanaka H,
Hori O,
Ogawa S,
Stern DM,
and
Schmidt AM.
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
Nature
405:
354-360,
2000[Medline].
64.
Take, M,
Tsutsui J,
Obama H,
Ozawa M,
Nakayama T,
Maruyama I,
Arima T,
and
Muramatsu T.
Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM).
J Biochem (Tokyo)
116:
1063-1068,
1994
65.
Uchimiya, H,
Furukawa T,
Okamoto M,
Nakajima Y,
Matsushita S,
Ikeda R,
Gotanda T,
Haraguchi M,
Sumizawa T,
Ono M,
Kuwano M,
Kanzaki T,
and
Akiyama S.
Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose.
Cancer Res
62:
2834-2839,
2002
66.
Xu, ZP,
Tsuji T,
Riordan JF,
and
Hu GF.
The nuclear function of angiogenin in endothelial cells is related to rRNA production.
Biochem Biophys Res Commun
294:
287-292,
2002[Web of Science][Medline].
67.
Yang, B,
Zhu W,
Johnson LB,
and
White FF.
The virulence factor AvrXa7 of Xanthomonas oryzae pv. oryzae is a type III secretion pathway-dependent nuclear-localized double-stranded DNA-binding protein.
Proc Natl Acad Sci USA
97:
9807-9812,
2000
This article has been cited by other articles:
|
|
 |
|
  R. N. Re and J. L. Cook The physiological basis of intracrine stem cell regulation Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H447 - H453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Re and J. L. Cook The Basis of an Intracrine Pharmacology J. Clin. Pharmacol., March 1, 2008; 48(3): 344 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, O. A. Carretero, C.-X. Lin, M. A. Cavasin, E. G. Shesely, J. J. Yang, T. L. Reudelhuber, and X.-P. Yang Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1900 - H1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Re Intracellular renin-angiotensin system: the tip of the intracrine physiology iceberg Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H905 - H906. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Varona, L. Blanco, J. I. Lopez, J. Gil, E. Agirregoitia, J. Irazusta, and G. Larrinaga Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma Am J Physiol Renal Physiol, February 1, 2007; 292(2): F780 - F788. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Pendergrass, D. B. Averill, C. M. Ferrario, D. I. Diz, and M. C. Chappell Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2.Lewis rat Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1497 - F1506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Re Intracellular Renin and the Nature of Intracrine Enzymes Hypertension, August 1, 2003; 42(2): 117 - 122. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
